Results 221 to 230 of about 8,117 (271)

Benralizumab for eosinophilic granulomatosis with polyangiitis

Annals of the Rheumatic Diseases, 2023
Background Benralizumab is effective in the treatment of eosinophilic asthma and is being investigated for the treatment of other eosinophil-associated diseases.
Adrien Cottu, M. Groh, C. Desaintjean, S. Marchand-Adam, L. Guillevin, X. Puéchal, Stacy Beaumesnil, E. Lazaro, M. Samson, C. Taillé, C. Durel, E. Diot, Sarah Nicolas, L. Guilleminault, M. Ebbo, P. Cathébras, C. Dupin, H. Yildiz, N. Belfeki, G. Pugnet, Pierre Chauvin, S. Jouneau, F. Lifermann, Jean-Philippe Martellosio, V. Cottin, B. Terrier   +25 more
semanticscholar   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Eosinophil Depletion with Benralizumab for Eosinophilic Esophagitis.

New England Journal of Medicine
BACKGROUND Benralizumab is an eosinophil-depleting anti-interleukin-5 receptor α monoclonal antibody. The efficacy and safety of benralizumab in patients with eosinophilic esophagitis are unclear.
M. Rothenberg, Evan S. Dellon, M. H. Collins, A. Bredenoord, I. Hirano, Kathryn A Peterson, Laura Brooks, J. Caldwell, Harald Fjällbrant, H. Grindebacke, C. N. Ho, Matthew Keith, C. Mccrae, Dominic Sinibaldi, Wendy I White, Catherine J Datto   +15 more
semanticscholar   +5 more sources

Efficacy and safety of benralizumab

Glavvrač (Chief Medical Officer)
The purpose of the review is to analyze Russian and foreign literature sources on the effectiveness and safety of benralizumab in the treatment of moderate and severe bronchial asthma.
К. О. Shnaider, M. L. Maksimov, S. A. Martynova   +2 more
semanticscholar   +2 more sources

Benralizumab for the Prevention of COPD Exacerbations [PDF]

New England Journal of Medicine, 2019
The efficacy and safety of benralizumab, an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody, for the prevention of exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) are not known.In the GALATHEA and TERRANOVA trials, we enrolled patients with COPD (at a ratio of approximately 2:1 on ...
Gerard J Criner, Bartolome R Celli, Christopher E Brightling   +2 more
exaly   +12 more sources

Benralizumab for Chronic Spontaneous Urticaria

New England Journal of Medicine, 2020
Benralizumab for Chronic Spontaneous Urticaria Benralizumab, an anti–interleukin-5-receptor antibody, was evaluated in a 24-week study involving 12 patients with chronic spontaneous urticaria.
Jonathan A Bernstein, Umesh Singh, Umesh Singh   +2 more
exaly   +3 more sources